Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan

PML caused by John Cunningham (JC) virus is a rare but an increasingly recognized entity. With the advent of newer immunomodulatory therapies with monoclonal antibodies, there is an increasing incidence of PML. Initially concern was restricted to patients treated for multiple sclerosis with natalizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lane, Michael A., Renga, Vijay, Pachner, Andrew R., Cohen, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326342/
https://www.ncbi.nlm.nih.gov/pubmed/25705531
http://dx.doi.org/10.1155/2015/892047
_version_ 1782356911313649664
author Lane, Michael A.
Renga, Vijay
Pachner, Andrew R.
Cohen, Jeffrey A.
author_facet Lane, Michael A.
Renga, Vijay
Pachner, Andrew R.
Cohen, Jeffrey A.
author_sort Lane, Michael A.
collection PubMed
description PML caused by John Cunningham (JC) virus is a rare but an increasingly recognized entity. With the advent of newer immunomodulatory therapies with monoclonal antibodies, there is an increasing incidence of PML. Initially concern was restricted to patients treated for multiple sclerosis with natalizumab but more case reports are being reported during treatment for other conditions like Crohn's disease and lymphoma with agents such as rituximab. We report the case of a 66-year-old woman who developed PML a year after completion of therapy with rituximab, ibritumomab, and bendamustine.
format Online
Article
Text
id pubmed-4326342
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-43263422015-02-22 Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan Lane, Michael A. Renga, Vijay Pachner, Andrew R. Cohen, Jeffrey A. Case Rep Neurol Med Case Report PML caused by John Cunningham (JC) virus is a rare but an increasingly recognized entity. With the advent of newer immunomodulatory therapies with monoclonal antibodies, there is an increasing incidence of PML. Initially concern was restricted to patients treated for multiple sclerosis with natalizumab but more case reports are being reported during treatment for other conditions like Crohn's disease and lymphoma with agents such as rituximab. We report the case of a 66-year-old woman who developed PML a year after completion of therapy with rituximab, ibritumomab, and bendamustine. Hindawi Publishing Corporation 2015 2015-01-29 /pmc/articles/PMC4326342/ /pubmed/25705531 http://dx.doi.org/10.1155/2015/892047 Text en Copyright © 2015 Michael A. Lane et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Lane, Michael A.
Renga, Vijay
Pachner, Andrew R.
Cohen, Jeffrey A.
Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
title Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
title_full Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
title_fullStr Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
title_full_unstemmed Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
title_short Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
title_sort late occurrence of pml in a patient treated for lymphoma with immunomodulatory chemotherapies, bendamustine, rituximab, and ibritumomab tiuxetan
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326342/
https://www.ncbi.nlm.nih.gov/pubmed/25705531
http://dx.doi.org/10.1155/2015/892047
work_keys_str_mv AT lanemichaela lateoccurrenceofpmlinapatienttreatedforlymphomawithimmunomodulatorychemotherapiesbendamustinerituximabandibritumomabtiuxetan
AT rengavijay lateoccurrenceofpmlinapatienttreatedforlymphomawithimmunomodulatorychemotherapiesbendamustinerituximabandibritumomabtiuxetan
AT pachnerandrewr lateoccurrenceofpmlinapatienttreatedforlymphomawithimmunomodulatorychemotherapiesbendamustinerituximabandibritumomabtiuxetan
AT cohenjeffreya lateoccurrenceofpmlinapatienttreatedforlymphomawithimmunomodulatorychemotherapiesbendamustinerituximabandibritumomabtiuxetan

Ejemplares similares